1-羟甲基环丙基乙腈 | 152922-71-9

• 物质功能分类: 化学试剂 - 有机试剂 - 氰化物/腈
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-羟甲基环丙基乙腈
• 中文别名: 2-(1-(羟甲基)环丙基)乙腈
• 英文名称: 1-(hydroxymethyl)cyclopropaneacetonitrile
• 英文别名: 2-(1-(hydroxymethyl)cyclopropyl)acetonitrile；1-hydroxymethylcyclopropyl acetonitrile；2-[1-(hydroxymethyl)cyclopropyl]acetonitrile
• CAS: 152922-71-9
• 化学式: C₆H₉NO
• mdl: MFCD08235273
• 分子量: 111.144
• InChiKey: WYOMLUMUVAPMKE-UHFFFAOYSA-N

物化性质

• 沸点：
  245.1±13.0 °C(Predicted)
• 密度：
  1.098±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(Hydroxymethyl)cyclopropaneacetonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(Hydroxymethyl)cyclopropaneacetonitrile
CAS number: 152922-71-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9NO
Molecular weight: 111.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

介绍

1-羟甲基环丙基乙腈是合成孟鲁司特钠的重要中间体。孟鲁司特钠由美国默克公司研制，是一种选择性白三烯D4受体拮抗剂。

合成过程

以季戊四醇为原料，首先进行溴化反应得到三溴新戊醇，再经乙酰化反应得到3-溴-2,2-双(溴甲基)丙基乙酸酯。接着，在催化剂和有机溶剂中与锌粉发生还原反应后，在氰化物溶液和有机溶剂中依次经历取代反应及水解反应制得1-羟甲基环丙基乙腈。整个工艺流程简单，所用原料易得，适用于工业化大规模生产。

用途

新药蒙特鲁卡斯特（Montelukast）的医药中间体。

反应信息

• 作为反应物：
  描述：

  1-羟甲基环丙基乙腈 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 以0.52 g的产率得到2-(1-(羟基甲基)环丙基)乙酸
  参考文献：
  名称：

  硼酸衍生物

  摘要：

  本发明涉及硼酸衍生物；本发明提供了式(I)化合物、或其前药、酯、醚、溶剂化物、多晶型物、异构体或上述任一种的药学上可接受的盐、或上述任两种以上的任意比例的混合物、包含这些化合物的药物组合物，以及其在治疗跟lmp7相关的疾病中的用途。

  公开号：

  CN114907389A
• 作为产物：
  描述：

  1-羟基甲基环丙烷乙酸甲酯 在 甲醇 、 copper(l) iodide 、 三溴化磷 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-羟甲基环丙基乙腈
  参考文献：
  名称：

  一种孟鲁司特钠侧链中间体及其制备方法

  摘要：

  本发明属于医药化学领域，具体涉及一种孟鲁司特钠侧链中间体及其制备方法。本发明提供的中间体化合物为6‑卤甲基‑5,7‑二氧杂螺[2.5]辛烷，其由1,1‑环丙基二甲醇为起始原料与2‑卤代‑1,1‑二甲氧基乙烷在固体酸催化下进行缩醛交换反应得到，该中间体用有机碱进行处理，然后用含有乙酸的水溶液进行水解，得到单乙酰基保护的二醇。本发明避免了单酰基保护的二醇的选择性差，二醇损失严重等问题，提高了原料的利用度，可以经济、方便的合成孟鲁司特钠侧链中间体。

  公开号：

  CN105541786B

文献信息

• N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase
  申请人：Merck Frosst Canada, Inc.

  公开号：US05604253A1

  公开（公告）日：1997-02-18

  The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  这项发明涵盖了式I的新化合物，以及一种治疗环氧合酶-2介导疾病的方法，包括向需要此类治疗的患者施用式I化合物的非毒性治疗有效量。 该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些含有式I化合物的药物组合物。
• SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20130023502A1

  公开（公告）日：2013-01-24

  The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R 1 , R 2 , R 4 , R 3 , R 5 and R 6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

  该发明涉及公式1中的新取代吡啶基嘧啶化合物， 其中环A是一个含有五个成员的饱和或不饱和碳环，该环可选地包含一个、两个或三个异原子，每个异原子独立地选自N、S和O组成， 其中R1、R2、R4、R3、R5和R6如权利要求书中所定义，并且环A进一步可选地被一个或两个进一步取代基取代，以及上述化合物的药用盐、二对映体、对映体、消旋体、水合物和溶剂化合物。
• [EN] THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] THIÉNOPYRIMIDINES CONTENANT UN GROUPE ALKYLE SUBSTITUÉ POUR DES COMPOSITIONS PHARMACEUTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011104340A1

  公开（公告）日：2011-09-01

  The present invention relates to novel thienopyhmidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及一类新型的噻吩并吡啶化合物，其具有通用公式，包括含有这些化合物的药物组合物，以及它们用于预防或治疗可以通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病的疗法。
• [EN] COMPOUND, COMPOSITIONS, AND METHODS<br/>[FR] COMPOSÉS, COMPOSITIONS, ET PROCÉDÉS
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2017087905A1

  公开（公告）日：2017-05-26

  Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  披露了具有LRRK2抑制剂活性的化合物。这些化合物具有公式(I)，包括立体异构体、互变异构体、药物可接受的盐和前药。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase
  申请人：Merck Frosst Canada, Inc.

  公开号：US05639780A1

  公开（公告）日：1997-06-17

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  这项发明涵盖了化合物I的新颖结构，可用于治疗环氧合酶-2介导的疾病。该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些药物组合物，其中包括化合物I。